MedTrace Logo

Safety Evaluation of the LGL102 in Obese Subjects Treated With OMS102

NCT01539850 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2012-02-28

No results posted yet for this study

Summary

The main objective of this study is to evaluate the LGL102 implant safety in obese to morbidly obese subjects treated with OMS102 system. The effect of the therapy on body weight changes will be also evaluated.

Conditions

Interventions

DEVICE

OMS102

Subjects will receive implanted OMS102 System.

Sponsors & Collaborators

  • IntraPace, Inc

    lead INDUSTRY

Principal Investigators

  • Thomas Horbach, MD · Stadtkrankenhaus Schwabach

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-04-30
Completion
2011-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01539850 on ClinicalTrials.gov